Association between cardiovascular outcomes and antihypertensive drug treatment in older women

JAMA

Volumn 292, Issue 23, 2004, Pages 2849-2859

  Wassertheil Smoller, Sylvia ^a   Psaty, Bruce ^b   Greenland, Philip ^c   Oberman, Albert ^d   Kotchen, Theodore ^e   Mouton, Charles ^f   Black, Henry ^g   Aragaki, Aaron ^h   Trevisan, Maurizio ⁱ  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^e MEDICAL COLLEGE OF WISCONSIN   (United States)

^f HOWARD UNIVERSITY COLLEGE OF MEDICINE   (United States)

^g RUSH UNIVERSITY MEDICAL CENTER   (United States)

^h Fred Hutchinson Cancer Research Center   (United States)

ⁱ UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; HYPERTENSION; INCIDENCE; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MONOTHERAPY; MORTALITY; OUTCOMES RESEARCH; POSTMENOPAUSE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; STROKE;

EID: 10344262902     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.292.23.2849     Document Type: Article

References (24)

1. Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med. 1997;157:2413-2446.
2. Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. The Fifth Report of the Joint National Committee on Detection Evaluation and Treatment of High Blood Pressure (JNCV). Arch Intern Med. 1993;153:154-183.
3. Siegel D, Lopez J. Trends in antihypertensive drug use in the United States. JAMA. 1997;278:1745-1748.
4. ALLHAT Officers and Coordinators for the for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. JAMA. 2002;288: 2981-2997.
5. Turnbull F. Effects of different blood-pressure-lowering regimens on major cardiovascular events. Lancet. 2003;362:1527-1535.
6. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. JAMA. 2003;289:2560-2572.
7. WHI Study Group. Design of the Women's Health Initiative clinical trial and observational study. Control Clin Trials. 1988;19:61-109 WHI Study.
8. Wassertheil-Smoller S, Anderson G, Psaty BM, et al. Hypertension and its treatment in postmenopausal women. Hypertension. 2000;36:780-789.
9. Psaty BM, Koepsell TD, Lin D, et al. Assessment and control for confounding by indication in observational studies. J Am Geriatr Soc. 1999;47:749-754.
10. Ainsworth BE, Haskell WL, Leon AS, et al. Compendium of physical activities: classification of energy costs of human activities. Med Sci Sports Exerc. 1993;25:71-80.
11. Rubin DB. Estimating causal effects from large data sets using propensity scores. Ann Intern Med. 1997; 127:757-763.
12. Rubin DB. Estimation from nonrandomized treatment comparisons using subclassification on propensity scores. Presented at: International Conference on Nonrandomized Comparative Clinical Studies; April 10-11, 1997; Heidelberg, Germany.
13. Psaty BM, Koepsell TD, Yanez ND, et al. Temporal patterns of antihypertensive medication use among older adults, 1989 through 1992. JAMA. 1995; 273:1436-1438.
14. Hypertension Detection and Follow-up Program Study Group. Five-year findings of the Hypertension Detection and Foliow-up Program: reduction in mortality of persons with high blood pressure including mild hypertension. JAMA. 1979;242:2562-2571.
15. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA. 1991; 265:3255-3264.
16. Staessen JA, Wang JG, Thijs L. Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet. 2001;358:1305-1315.
17. Pahor M, Psaty BM, Alderman MH, et al. Health outcomes associated with calcium antagonists compared with other first-line antihypertensive therapies. Lancet. 2000;356:1949-1954.
18. Opie LH. Calcium channel blockers in hypertension. Am 1 Hypertens. 2001;14:1074-1081.
19. Gueyffier F, Boutities F, Boissel J, et al; the INDANA Investigators. Effect of anti-hypertensive drug treatment on cardiovascular outcomes in men and women. Ann Intern Med. 1997;126:761-767.
20. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001;358:1033-1041.
21. Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine. Lancet. 2004;363:2022-2031.
22. Davis BR, Cutler JA, Gordon DJ, et al; ALLHAT Research Group. Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Am J Hypertens. 1996;9:342-360.
23. Ball SG. Discontinuation of doxazosin arm of ALLHAT. Lancet. 2000;355:1558.
24. Messerli FH. Implications of discontinuation of doxazosin arm of ALLHAT. Lancet. 2000;355:863-864.